Mylan recently announced that its shareholders had approved its merger with Pfizer’s Upjohn, to form a new company called Viatris. One asset within Upjohn is Greenstone, a generic manufacturer that focuses on authorized generics. Given the news of the merger, we were interested to better understand the concentration risk on the U.S. generic marketplace by the marriage of Mylan and Greenstone. The good news is that we already have a tool that gives us an idea of who has what market share (using Medicaid data) for every drug. While not a complete assessment of our nation’s generic manufacturer market share, the Medicaid data provides a substantive snapshot of the overall market distribution for the production of each generic drug. Here’s what we found.

Read More